The MenAfriVac mass vaccination campaign delivered over 270 million doses of menin-gococcal A protein-polysaccharide conjugate (MenA) vaccine to children and young adults in 21 of the 26 countries of the meningitis belt between 2010 and 2018, which resulted in a marked decline in cases of disease;14 the meningitis belt was first defined as a “region south of the Sahara between latitudes 4 and 160N” and was later expanded to include the Sahelian parts of Benin, Cameroon, Ethiopia, The Gambia, Ghana, Mali, and Senegal (appendix).16 Here, MEN1 is linked to infectious meningitis.